Top

Published in:

01-02-2011

Update on Strongyloidiasis in the Immunocompromised Host

Authors: Luis A. Marcos, Angélica Terashima, Marco Canales, Eduardo Gotuzzo

Published in: Current Infectious Disease Reports | Issue 1/2011

Abstract

Immunocompromised persons are the most vulnerable population at risk for developing life-threatening clinical syndromes associated with strongyloidiasis, such as hyperinfection syndrome (HS) or dissemination. This review focuses on describing Strongyloides infection in the immunocompromised host, including immune response against this infection, analyzing the cases with HS published during the past 4 years in the United States, and describing the most sensitive diagnostic tools and the most effective treatment for each clinical syndrome. Strongyloidiasis is becoming an important parasitic disease in the United States, especially in the immunocompromised immigrant population. Because the transplant population is particularly at risk for developing HS, both recipients and donors should be screened for Strongyloides. Clinicians should also be aware that the development of HS can follow unexpectedly a few days after appropriate anthelminthic therapy. Highly sensitive screening tests are still not available in the major tertiary medical centers. Parenteral ivermectin has been used in some severe cases. Further therapy developments and improving diagnostic tools are warranted.

Bethony J, Brooker S, Albonico M, et al. Soil-transmitted helminth infections: ascariasis, trichuriasis, and hookworm. Lancet 2006; 367: 1521–1532.PubMedCrossRef

• Marcos LA, Terashima A, DuPont HL, Gotuzzo E. Strongyloides hyperinfection Syndrome: An Emerging Global Infectious Disease. Trans R Soc Trop Med Hyg 2008; 102: 314-318. This article provides a brief overview of strongyloidiasis worldwide, regarding clinical syndromes, risk factors, diagnosis, and treatment.PubMedCrossRef

Genta RM. Dysregulation of strongyloidiasis: a new hypothesis. Clin Microbiol Rev. 1992; 5:345–55.PubMed

•• Croker C, Reporter R, Redelings, M, Mascola L. Strongyloidiasis-related deaths in the United States, 1991–2006. Am. J. Trop. Med. Hyg 2010; 83: 422–426. This article provides a perspective on strongyloidiasis in the United States and mortality.PubMedCrossRef

Jankovic D, Steinfelder S, Kullberg M, Sher A. Mechanisms underlying helminth-induced Th2 polarization: default, negative or positive pathways? In: Capron, M. Trottein, F. (Eds.), Parasites and Allergy. Chem. Immunol. 2006; 90: 65–81

Finkelman FD, Shea-Donohue T, Goldhill J, et al. Cytokine regulation of host defense against parasitic gastrointestinal nematodes: lessons from studies with rodent models. Annual Review of Immunology 1997; 15: 505–533.PubMedCrossRef

Ilic N, Colic M, Gruden-Movsesijan A, et al. Characterization of rat bone marrow dendritic cells initially primed by Trichinella spiralis antigens. Parasite Immunol. 2008; 30:491–495.PubMedCrossRef

Wilkes CP, Bleay C, Paterson S, Viney ME. The immune response during a Strongyloides ratti infection of rats. Parasite Immunol. 2007;29(7):339–46.PubMedCrossRef

Abe H, Sugaya, K, Ishida WI, et al. Intestinal protection against Strongyloides ratti and mastocytosis induced by administration of interleukin-3 in mice. Immunology 1993; 80: 116–121.PubMed

10.

Artis D, Grencis RK. T helper cell cytokine responses during intestinal nematode infection: induction, regulation and effector function. In: M.W. Kennedy and W. Harnett, Editors, Parasitic Nematodes: Molecular Biology, Biochemistry and Immunology, CABI Publishing, Wallingford; 2001: 331–371.

11.

Miller HRP. The protective mucosal response against gastrointestinal nematodes in ruminants and laboratory animals, Vet. Immunol. Immunopathol. 1984; 5: 167–259.CrossRef

12.

Rotman H, Yutanawiboonchai W, Brigandi R, et al. Strongyloides stercoralis: eosinophil-dependent immune-mediated killing of third stage larvae in BALB/cByJ mice. Experimental Parasitology 1996; 82: 267–278.PubMedCrossRef

13.

Siddiqui AA, Berk SL, Genta RM: Strongyloidiasis in tropical infectious diseases. In Tropical Infectious Diseases: Principles, Pathogens, and Practice. Edited by: Guerrant RL, Walker DH, Weller RF. Philadelphia: Elsevier; 2005:1274–1285.

14.

Rotman H, Schnyder-Candrian S, Scott P, et al. IL-12 eliminates the Th-2 dependent protective immune response of mice to larval Strongyloides stercoralis. Parasite Immunology 1997, 19: 29–39.PubMedCrossRef

15.

Kerepesi LA, Hess JA, Nolan TJ, et al.: Complement component C3 is required for protective innate and adaptive immunity to larval strongyloides stercoralis in mice. J Immunol. 2006;176: 4315–22PubMed

16.

Abraham D, Rotman H, Haberstroh H, et al. Strongyloides stercoralis: protective immunity to third-stage larvae in BALB/cByJ mice. Experimental Parasitology 1995, 80: 297–307.PubMedCrossRef

17.

Brigandi R, Rotman H, Yutanawiboonchai W, et al. Strongyloides stercoralis: role of antibody and complement in immunity to the third stage larvae in BALB/cByJ mice. Experimental Parasitology 1996, 82: 279–289.PubMedCrossRef

18.

Ligas JA, Kerepesi LA, Galioto AM, et al. Specificity and mechanism of immunoglobulin M (IgM)- and IgG-dependent protective immunity to larval Strongyloides stercoralis in mice. Infect Immun. 2003; 71: 6835–43PubMedCrossRef

19.

Brigandi R, Rotman H, Nolan T, et al.: Chronicity in Strongyloides stercoralis infections: Dichotomy of the protective immune response to infective and autoinfective larvae in a mouse model. Am J Trop Med Hyg 1997; 56: 640–646.PubMed

20.

Rotman H, Yutanawiboonchai W, Brigandi R, et al. Strongyloides stercoralis: complete life cycle in SCID mice. Experimental Parasitology 1995, 81: 136–139.PubMedCrossRef

21.

Fernandes A, Pereira AT, Eschenazi PD, et al. Evaluation of the immune response against Strongyloides venezuelensis in antigen-immunized or previously infected mice. Parasite Immunol. 2008; 30: 139–149.PubMedCrossRef

22.

Kerepesi LA, Nolan TJ, Schad GA, et al. Human immunoglobulin G mediates protective immunity and identifies protective antigens against larval Strongyloides stercoralis in mice. J Infect Dis. 2004; 189: 1282–1290PubMedCrossRef

23.

Machado ER, Ueta MT, Lourenço EV, et al. Comparison of immune responses in mice infected with different strains of Strongyloides venezuelensis. Parasite Immunol. 2007; 29: 549–557.PubMedCrossRef

24.

Bancroft AJ, Else KJ, Grencis RK. Low-level infection with Trichuris muris significantly affects the polarization of the CD4 response, Eur. J. Immunol. 1994; 24: 3113–3118.PubMedCrossRef

25.

Bleay C, Wilkes CP, Paterson S, Viney M. Density-dependent immune responses against the gastrointestinal nematode Strongyloides ratti. International Journal for Parasitology 2007; 37: 1501–1509.PubMedCrossRef

26.

Paterson S, Wilkes C, Bleay C, Viney ME. Immunological responses elicited by different infection regimes with Strongyloides ratti. PLoS ONE 2008; 3: e2509.PubMedCrossRef

27.

Allen JE, Maizels RM. Immunology of human helminth infection. International Archives of Allergy and Immunology 1996; 109: 3–10PubMedCrossRef

28.

Genta R, Lillibridge J. Prominence of IgG4 antibodies in the human responses to Strongyloides stercoralis infection. JID 1989; 160: 692–699.PubMed

29.

Atkins N, Conway D, Lindo J, et al.: L3 antigen-specific antibody isotype responses in human strongyloidiasis: correlations with larval output. Parasite Immunology 1999, 21: 517–526.PubMedCrossRef

30.

Satoh M, Toma H, Sato Y, et al. Production of a high level of specific IgG4 antibody associated with resistance to albendazole treatment in HLA-DRB1*0901- positive patients with strongyloidiasis. Am J Trop Med Hyg 1999; 61: 668–671.PubMed

31.

Marcos LA, Terashima A, Samalvides F, et al. Thiabendazole for the control of Strongyloides stercoralis infection in a hyperendemic area in Peru. Rev. Gastroenterol. Peru 2005; 25: 341–348.PubMed

32.

Lagacé-Wiens P, Harding G. A Canadian immigrant with coinfection of Strongyloides stercoralis and human T-lymphotropic virus 1. CMAJ 2007; 177: 451-453.PubMed

33.

Gotuzzo E, Terashima A, Alvarez H, et al. Strongyloides stercoralis hyperinfection associated with human T cell lymphotropic virus type-1 infection in Peru. Am J Trop Med Hyg. 1999; 60: 146–149.PubMed

34.

Terashima A, Gotuzzo E, Alvarez H, et al. Strongyloides Stercoralis: Clinical severe forms associated to HTLV-1 infection. Rev Gastroenterol Peru. 1999;19: 35–40PubMed

35.

Freedman DO. Experimental infection of human subject with Strongyloides species. Rev. Infect. Dis. 1991; 13:1221–1226.PubMed

36.

Herrera J, Marcos L, Terashima A, et al. Factors associated with Strongyloides stercoralis infection in an endemic area in Peru. Rev Gastroenterol Peru. 2006; 26: 357–362.PubMed

37.

•• González A, Gallo M, Valls ME, et al.: Clinical and epidemiological features of 33 imported Strongyloides stercoralis infections. Trans R Soc Trop Med Hyg. 2010;104: 613–616. Interesting article that describes the clinical-epidemiological characteristics of imported strongyloidiasis in Europe.PubMedCrossRef

38.

Marcos LA, Lozano D, Calvo G, et al.: Strongyloides stercoralis associated with nephritic syndrome in a child with intestinal neuronal dysplasia. Neotrop. helminthol. 2007; 1: 37–42.

39.

Vadlamudi RS, Chi DS, Krishnaswamy G. Intestinal strongyloidiasis and hyperinfection syndrome. Clin. Mol. Allergy 2006; 30: 4–8.

40.

• Cruz RJ Jr, Vincenzi R, Ketzer BM. Duodenal obstruction - an unusual presentation of Strongyloides stercoralis enteritis: a case report. World J Emerg Surg. 2010; 5: 23. This case report also contains a literature review of duodenal obstruction caused by Strongyloides stercoralis infection between 1970 and 2010.

41.

Roboz GJ, Rafii S. Interleukin-5 and the regulation of eosinophil production. Curr. Opin. Hematol. 1999; 6:164PubMedCrossRef

42.

Lalani T, Simmons RK, Ahmed AR. Biology of IL-5 in health and disease. Ann. Allergy Asthma Immunol. 1999; 82:317PubMedCrossRef

43.

Schwenger GT, Sanderson CJ. New directions in understanding interleukin-5 gene expression. Leukemia Lymphoma 1998; 28:443PubMed

44.

Korenaga M, Hitoshi Y, Yamaguchi N, et al. The role of interleukin-5 in protective immunity to Strongyloides venezuelensis infection in mice. Immunology. 1991; 72: 502–507.PubMed

45.

Herbert D, Lee J, Lee N, et al. Role of IL-5 in Innate and Adaptive Immunity to Larval Strongyloides stercoralis in Mice. The Journal of Immunology 2000, 165: 4544–4551.PubMed

46.

Vaiyavatjamai P, Boitano JJ, Techasintana P, Tungtrongchitr A. Immunocompromised group differences in the presentation of intestinal strongyloidiasis. Jpn J Infect Dis. 2008; 61: 5–8PubMed

47.

Hirata T, Uchima N, Kishimoto K, et al. Impairment of host immune response against Strongyloides stercoralis by human T cell lymphotropic virus type 1 infection. Am. J. Trop. Med. Hyg. 2006; 74: 246–249.PubMed

48.

Carvalho EM, Bacellar O, Porto AF, et al. Cytokine profile and immunomodulation in asymptomatic human T-lymphotropic virus type 1-infected blood donors. J Acquir Immune Defic Syndr 2001; 27: 1–6.PubMed

49.

Robinson RD, Lindo JF, Neva FA, et al. Immunoepidemiologic studies of Strongyloides stercoralis and human T lymphotropic virus type I infections in Jamaica. J Infect Dis 1994; 169: 692–696.PubMed

50.

Porto AF, Neva FA, Bittencourt H, et al. HTLV-1 decreases Th2 type of immune response in patients with strongyloidiasis. Parasite Immunol 2001; 23:503–507.PubMedCrossRef

51.

Satoh M, Toma H, Sato Y, et al. Reduced efficacy of treatment of strongyloidiasis in HTLV-I carriers related to enhanced expression of IFN-γ and TGF-β1. Clin. Exp. Immunol 2002, 127: 354–359.PubMedCrossRef

52.

Carvalho EM, Da Fonseca PA. Epidemiological and clinical interaction between HTLV-1 and Strongyloides stercoralis. Parasite Immunol. 2004; 26: 487–497.PubMedCrossRef

53.

Satoh M, Toma H, Sugahara K, et al. Involvement of IL-2/IL-2R system activation by parasite antigen in polyclonal expansion of CD4+ 25+ HTLV-1-infected T-cells in human carriers of both HTLV-1 and S. stercoralis. Oncogene 2002; 21: 2466–2475.PubMedCrossRef

54.

Neva F, Oliveira J, Gam A, et al. Interferon-γ and Interleukin-4 Responses in relation to serum IgE levels in persons infected with Human T Lymphotropic Virus Type I and Strongyloides stercoralis. JID 1998; 178: 1856–1859.PubMedCrossRef

55.

Ratner L, Grant C, Zimmerman B, et al. Effect of treatment of Strongyloides infection on HTLV-1 expression in a patient with adult T-cell leukemia. Am J Hematol. 2007; 82: 929–931.PubMedCrossRef

56.

Terashima A, Alvarez H, Tello R, et al. Treatment failure in intestinal strongyloidiasis: an indicator of HTLV-I infection. Int. J. Infect. Dis. 2002; 6: 28–30.PubMedCrossRef

57.

Gotuzzo E, Arango C, de Queiroz-Campos A, Istúriz RE. Human T-cell lymphotropic virus-I in Latin America. Infect Dis Clin North Am. 2000; 14: 211–239.PubMedCrossRef

58.

Lucas SB. Missing infections in AIDS. Trans Roy Soc Trop Med Hyg 1990; 84:34–8.PubMedCrossRef

59.

Tanaka M, Hirabayashi Y, Gatanaga H, et al. Reduction in interleukin-2-producing cells but not Th1 to Th2 shift in moderate and advanced stages of human immunodeficiency virus type-1-infection: direct analysis of intracellular cytokine concentrations in CD4+ CD8- T cells. Scand. J. Immunol. 1999; 50:550–554.PubMedCrossRef

60.

Barker E, Mackewicz CE, Levy JA. Effects of TH1 and TH2 cytokines on CD8+ cell response against human immunodeficiency virus: implications for long-term survival. Proc. Natl. Acad. Sci. USA 1995; 92: 11135–11139.PubMedCrossRef

61.

Valdez H, Lederman MM. Cytokines and cytokine therapies in HIV infection. AIDS Clin. Rev. 1997; 98: 187–228.

62.

Viney ME, Brown M, Omoding NE, et al. Does HIV Infection Not Lead to Disseminated Strongyloidiasis? HIV and Strongyloidiasis. JID 2004; 190: 2175–2180.PubMedCrossRef

63.

Culshaw RJ, Bancroft GJ, McDonald V. Gut intraepithelial lymphocytes induce immunity against Cryptosporidium infection through a mechanism involving gamma interferon production. Infect. Immun. 1997; 65: 3074–3079.PubMed

64.

Petithory JC, Derouin F. AIDS and strongyloidiasis in Africa. Lancet 1987; 1: 921.PubMedCrossRef

65.

Grein JD, Mathisen GE, Donovan S, Fleckenstein L. Serum ivermectin levels after enteral and subcutaneous administration for Strongyloides hyperinfection: a case report. Scand J Infect Dis. 2010; 42: 234–236.PubMedCrossRef

66.

Brown M, Cartledge JD, Miller RF. Dissemination of Strongyloides stercoralis as an immune restoration phenomenon in an HIV-1-infected man on antiretroviral therapy. Int J STD AIDS. 2006; 17: 560–561.PubMedCrossRef

67.

Celedon JC, Mathur-Wagh U, Fox J, et al.: Systemic strongyloidiasis in patients infected with the human immunodeficiency virus. A report of 3 cases and review of the literature. Medicine (Baltimore). 1994; 73: 256–263.

68.

Hong IS, Zaidi SY, McEvoy P, Neafie RC. Diagnosis of Strongyloides stercoralis in a peritoneal effusion from an HIV-seropositive man. A case report. Acta Cytol. 2004; 48: 211–214.

69.

Cimerman S, Cimerman B, Lewi DS. Prevalence of intestinal parasitic infections in patients with acquired immunodeficiency syndrome in Brazil. Int J Inf Dis 1999; 3:203–206.CrossRef

70.

Assefa S, Erko B, Medhin G, et al.: Intestinal parasitic infections in relation to HIV/AIDS status, diarrhea and CD4 T-cell count. BMC Infect Dis. 2009; 9: 155.PubMedCrossRef

71.

Lindo JF, Dubon JM, Ager AL, et al. Intestinal parasitic infections in human immunodeficiency virus (HIV)-positive and HIV-negative individuals in San Pedro Sula, Honduras. Am J Trop Med Hyg. 1998; 58: 431–435.PubMed

72.

Safdar A, Malathum K, Rodriguez SJ, et al.: Strongyloidiasis in patients at a comprehensive cancer center in the United States. Cancer. 2004; 100: 1531–1536.PubMedCrossRef

73.

• Wirk B, Wingard JR. Strongyloides stercoralis hyperinfection in hematopoietic stem cell transplantation. Transpl Infect Dis. 2009; 11: 143–148. This article describes the cases of strongyloidiasis and HSCT patients with high mortality, and highlights the fact that no current standard therapy exists for immunocompromised patients with hyperinfection or disseminated disease.PubMedCrossRef

74.

Wolfe RA, Roys EC, Merion RM. Trends in organ donation and transplantation in the United States, 1999–2008. Am J Transplant. 2010; 10: 961–972.PubMedCrossRef

75.

Weiser JA, Scully BE, Bulman WA, et al.: Periumbilical parasitic thumbprint purpura: Strongyloides hyperinfection syndrome acquired from a cadaveric renal transplant. Transpl Infect Dis. 2010.

76.

• Patel G, Arvelakis A, Sauter BV, et al.: Strongyloides hyperinfection syndrome after intestinal transplantation. Transpl Infect Dis. 2008; 10: 137–141. This case speculates that the donor can be a potential source of the infection.PubMedCrossRef

77.

Hoy WE, Roberts NJ, Bryson MF, et al. Transmission of strongyloidiasis by kidney transplant? Disseminated strongyloidiasis in both recipients of kidney allografts from a single cadaver donor. JAMA 1981; 246: 1937–1939.PubMedCrossRef

78.

Ben-Youssef R, Baron P, Edson F, et al.: Strongyloides stercoralis infection from pancreas allograft: case report. Transplantation 2005; 80: 997–998.PubMedCrossRef

79.

• Fitzpatrick MA, Caicedo JC, Stosor V, Ison MG. Expanded infectious diseases screening program for Hispanic transplant candidates. Transpl Infect Dis. 2010; 12: 336–341. This article reports the first study to screen pre-transplant patients for strongyloidiasis.PubMedCrossRef

80.

El Masry HZ, O’Donnell J. Fatal strongyloides hyperinfection in heart transplantation. J Heart Lung Transplant. 2005; 24: 1980–1983.PubMedCrossRef

81.

•• Santiago M, Leitão B. Prevention of strongyloides hyperinfection syndrome: a rheumatological point of view. Eur J Intern Med. 2009; 20: 744–748. This article summarizes the therapeutic options with cure rates and doses for strongyloidiasis.PubMedCrossRef

82.

Schaeffer MW, Buell JF, Gupta M, et al. Strongyloides hyperinfection syndrome after heart transplantation: case report and review of the literature. J Heart Lung Transplant. 2004; 23: 905–911.PubMedCrossRef

83.

Simpson WG, Gerhardstein DC, Thompson JR. Disseminated Strongyloides stercoralis infection. South Med J. 1993; 86: 821–825.PubMedCrossRef

84.

Krishnamurthy R, Dincer HE, Whittemore D. Strongyloides stercoralis hyperinfection in a patient with rheumatoid arthritis after anti-TNF-alpha therapy. J Clin Rheumatol. 2007; 13: 150–152.PubMedCrossRef

85.

Marchi Blatt J, Cantos GA: Evaluation of techniques for the diagnosis of Strongyloides stercoralis in human immunodeficiency virus (HIV) positive and HIV negative individuals in the city of Itajai, Brazil. Braz J Infect Dis 2003, 7:402–408.PubMed

86.

Rose CE, Paciullo CA, Kelly DR, et al.: Fatal Outcome of Disseminated Strongyloidiasis despite Detectable Plasma and Cerebrospinal Levels of Orally Administered Ivermectin. J Parasitol Res. 2009;

87.

Gyorkos TW, Genta RM, Viens P, MacLean JD. Seroepidemiology of Strongyloides infection in the Southeast Asian refugee population in Canada. Am J Epidemiol. 1990; 132: 257–264.PubMed

88.

Marcos LA, Canales M, Terashima A. Métodos de diagnóstico para Strongyloides stercoralis en el Perú. Rev peru Parasitol 2010;17(1): in press.

89.

Siddiqui AA, Berk SL. Diagnosis of Strongyloides stercoralis infection. Clin Infect Dis. 2001; 33: 1040–1047.PubMedCrossRef

90.

Igual-Adell R, Oltra-Alcaraz C, Soler-Company E, et al. Efficacy and safety of ivermectin and thiabendazole in the treatment of strongyloidiasis. Expert Opin Pharmacother. 2004; 5: 2615–2619.PubMedCrossRef

91.

Datry A, Hilmarsdottir I, Mayorga-Sagastume R, et al.: Treatment of Strongyloides stercoralis infection with ivermectin compared with albendazole: results of an open study of 60 cases. Trans. R. Soc. Trop. Med. Hyg. 1994; 88: 344–345.PubMedCrossRef

92.

Marti H, Haji HJ, Savioli L, et al.: A comparative trial of a single-dose ivermectin versus three days of albendazole for treatment of Strongyloides stercoralis and other soil-transmitted helminth infections in children. Am. J. Trop. Med. Hyg. 1996; 55: 477–481.PubMed

93.

Alvarez H, Terashima A. Nematodiosis and Strongyloidosis. Diagnostico 2000; 39: 112-115.

94.

Terashima A. Parasitosis. In: Topicos Selectos en Medicina Interna. Gastroenterologia, Tubo Digestivo, Higado, Pancreas y Vias Biliares, 2006.

95.

Gupta S, Jain A, Fanning TV, et al.: An unusual cause of alveolar hemorrhage post hematopoietic stem cell transplantation: a case report. BMC Cancer. 2006; 6: 87.PubMedCrossRef

96.

• Hunter CJ, Petrosyan M, Asch M. Dissemination of Strongyloides stercoralis in a patient with systemic lupus erythematosus after initiation of albendazole: a case report. J Med Case Reports. 2008; 2: 156. This case shows that albendazole should not be used in hyperinfection syndrome because it has low effectiveness.PubMedCrossRef

97.

Marty FM, Lowry CM, Rodriguez M, et al.: Treatment of human disseminated strongyloidiasis with a parenteral veterinary formulation of ivermectin. CID 2005; 41: e5–e8.CrossRef

98.

Satou T, Koga M, Koike K, et al.: Nematocidal activities of thiabendazole and ivermectin against the larvae of Strongyloides ratti and S. venezuelensis. Vet Parasitol 2001, 99: 311–322.PubMedCrossRef

99.

Satou T, Koga M, Matsuhashi R, et al. Assay of nematocidal activity of isoquinoline alkaloids using third stage larvae of Strongyloides ratti and S. venezuelensis. Vet Parasitol 2002, 104: 131–138.

100.

Tarr PE, Miele PS, Peregoy KS, et al. Case report: Rectal adminstration of ivermectin to a patient with Strongyloides hyperinfection syndrome. Am J Trop Med Hyg. 2003; 68: 453–455.PubMed

101.

Chiodini PL, Reid AJ, Wiselka MJ, et al.: Parenteral ivermectin in Strongyloides hyperinfection. Lancet. 2000; 355: 43–44.PubMedCrossRef

102.

Hauber HP, Galle J, Chiodini PL, et al. Fatal outcome of a hyperinfection syndrome despite successful eradication of Strongyloides with subcutaneous ivermectin. Infection. 2005; 33: 383–386.PubMedCrossRef

103.

• Miller MA, Church LW, Salgado CD. Strongyloides hyperinfection: a treatment dilemma. Am J Med Sci. 2008; 336: 358–361. This article reports a successful treatment with subcutaneous ivermectin in a patient with HS.PubMedCrossRef

104.

Maraha BA, Buiting AG, Hol C, et al. The risk of Strongyloides stercoralis transmission from patients with disseminated strongyloidiasis to the medical staff. J Hosp Infect 2001; 49: 222–224PubMedCrossRef

105.

Muennig P, Pallin D, Challah C, Khan K. The cost-effectiveness of ivermectin vs. albendazole in the presumptive treatment of strongyloidiasis in immigrants to the United States. Epidemiol Infect. 2004; 132: 1055–1063PubMedCrossRef

106.

Muennig P, Pallin D, Sell RL, Chan MS. The cost effectiveness of strategies for the treatment of intestinal parasites in immigrants. N Engl J Med. 1999; 340: 773–779.PubMedCrossRef

107.

Jones N, Cocchiarella A, Faris K, Heard SO. Pancreatitis associated with Strongyloides stercoralis infection in a patient chronically treated with corticosteroids. J Intensive Care Med. 2010; 25: 172–174.PubMedCrossRef

108.

Russo JJ, Rusiecki RS, Vincek V, et al.: Purpuric eruption in a patient treated with systemic steroids. Arch Dermatol. 2010; 146: 191–196.PubMedCrossRef

109.

Ali HA, Walkenstein M. Bilateral nodular pulmonary infiltrates in an immunocompromised host. Thorax. 2008; 63: 746–753.PubMedCrossRef

110.

Aregawi D, Lopez D, Wick M, et al.: Disseminated strongyloidiasis complicating glioblastoma therapy: a case report. J Neurooncol. 2009; 94: 439–443.PubMedCrossRef

111.

Dalia S, Colvin GA. Eosinophilia secondary to strongyloides in Rhode Island. Med Health R I. 2010; 93: 92–93.PubMed

112.

Riedel DJ, Roddy KM, Sajadi MM. Abdominal pain and bacterial meningitis in a previously healthy young adult. Clin Infect Dis. 2008; 46: 1479–80.CrossRef

113.

•• Roxby AC, Gottlieb GS, Limaye AP. Strongyloidiasis in Transplant Patients. CID 2009; 49: 1411–1423. This article is an excellent review of strongyloidiasis in the transplant population.CrossRef

Title: Update on Strongyloidiasis in the Immunocompromised Host
Authors: Luis A. Marcos
Angélica Terashima
Marco Canales
Eduardo Gotuzzo
Publication date: 01-02-2011
Publisher: Current Science Inc.
Published in: Current Infectious Disease Reports / Issue 1/2011
Print ISSN: 1523-3847
Electronic ISSN: 1534-3146
DOI: https://doi.org/10.1007/s11908-010-0150-z

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2011

The Rapidly Evolving Research on Vitamin D Among HIV-Infected Populations

Current Concepts of the Intestinal Microbiota and the Pathogenesis of Infection

Clinical Trial Report: TMC278 (Rilpivirine) Versus Efavirenz as Initial Therapy in Treatment-Naïve, HIV-1–Infected Patients

Prospects for Development of a Vaccine to Prevent and Control Vaginal Candidiasis

Inflammatory Markers Associated with Coronary Heart Disease in Persons with HIV Infection

Growing Old with HIV

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials